Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35

Journal of Controlled Release

Volumn 148, Issue 2, 2010, Pages 212-218

  Sakurai, Fuminori ^a,b   Nakashima, Kazuko ^a   Yamaguchi, Tomoko ^a,b   Ichinose, Takako ^a   Kawabata, Kenji ^a,b   Hayakawa, Takao ^c   Mizuguchi, Hiroyuki ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

Adenovirus serotype 35 vectors; CD46; Dendritic cells; Fiber substituted Ad vectors; Inflammatory cytokine; Innate immunity

Indexed keywords

ADENOVIRUS SEROTYPE 35 VECTORS; CD46; CYTOKINES; DENDRITIC CELLS; INNATE IMMUNITY;

BACTERIOPHAGES; CELLS; FIBERS; IMMUNOLOGY; MAMMALS;

VECTORS;

ADENOVIRUS VECTOR; MEMBRANE COFACTOR PROTEIN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; UPREGULATION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD46; CAPSID PROTEINS; CELLS, CULTURED; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INJECTIONS, INTRAVENOUS; INTERFERON-BETA; INTERLEUKIN-12; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649316042     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.08.025     Document Type: Article

References (58)

1. Okada N., Saito T., Masunaga Y., Tsukada Y., Nakagawa S., Mizuguchi H., Mori K., Okada Y., Fujita T., Hayakawa T., Mayumi T., Yamamoto A. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res. 2001, 61:7913-7919.
2. de Gruijl T.D., Ophorst O.J., Goudsmit J., Verhaagh S., Lougheed S.M., Radosevic K., Havenga M.J., Scheper R.J. Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells. J. Immunol. 2006, 177:2208-2215.
3. Kanagawa N., Koretomo R., Murakami S., Sakurai F., Mizuguchi H., Nakagawa S., Fujita T., Yamamoto A., Okada N. Factors involved in the maturation of murine dendritic cells transduced with adenoviral vector variants. Virology 2008, 374:411-420.
4. Rea D., Havenga M.J., van Den Assem M., Sutmuller R.P., Lemckert A., Hoeben R.C., Bout A., Melief C.J., Offringa R. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 2001, 166:5236-5244.
5. O'Brien K.L., Liu J., King S.L., Sun Y.H., Schmitz J.E., Lifton M.A., Hutnick N.A., Betts M.R., Dubey S.A., Goudsmit J., Shiver J.W., Robertson M.N., Casimiro D.R., Barouch D.H. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 2009, 15:873-875.
6. Koup R.A., Lamoreaux L., Zarkowsky D., Bailer R.T., King C.R., Gall J.G., Brough D.E., Graham B.S., Roederer M. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J. Virol. 2009, 83:6318-6322.
7. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., Abbink P., Coffey R.T., Grandpre L.E., Seaman M.S., Landucci G., Forthal D.N., Montefiori D.C., Carville A., Mansfield K.G., Havenga M.J., Pau M.G., Goudsmit J., Barouch D.H. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
8. Mizuguchi H., Hayakawa T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 2002, 285:69-77.
9. Shayakhmetov D.M., Papayannopoulou T., Stamatoyannopoulos G., Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 2000, 74:2567-2583.
10. Stecher H., Shayakhmetov D.M., Stamatoyannopoulos G., Lieber A. A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol. Ther. 2001, 4:36-44.
11. Segerman A., Atkinson J.P., Marttila M., Dennerquist V., Wadell G., Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 2003, 77:9183-9191.
12. Gaggar A., Shayakhmetov D.M., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 2003, 9:1408-1412.
13. Ophorst O.J., Kostense S., Goudsmit J., De Swart R.L., Verhaagh S., Zakhartchouk A., Van Meijer M., Sprangers M., Van Amerongen G., Yuksel S., Osterhaus A.D., Havenga M.J. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004, 22:3035-3044.
14. Holterman L., Vogels R., van der Vlugt R., Sieuwerts M., Grimbergen J., Kaspers J., Geelen E., van der Helm E., Lemckert A., Gillissen G., Verhaagh S., Custers J., Zuijdgeest D., Berkhout B., Bakker M., Quax P., Goudsmit J., Havenga M. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J. Virol. 2004, 78:13207-13215.
15. Stone D., Ni S., Li Z.Y., Gaggar A., DiPaolo N., Feng Q., Sandig V., Lieber A. Development and assessment of human adenovirus type 11 as a gene transfer vector. J. Virol. 2005, 79:5090-5104.
16. Sakurai F., Mizuguchi H., Hayakawa T. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. Gene Ther. 2003, 10:1041-1048.
17. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J.C., Korioth-Schmitz B., Newberg M.H., Gorgone D.A., Lifton M.A., Panicali D.L., Nabel G.J., Letvin N.L., Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 2004, 172:6290-6297.
18. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., Nanda A., Ewald B.A., Gorgone D.A., Lifton M.A., Goudsmit J., Havenga M.J., Barouch D.H. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol. 2005, 79:9694-9701.
19. Havenga M.J., Lemckert A.A., Ophorst O.J., van Meijer M., Germeraad W.T., Grimbergen J., van Den Doel M.A., Vogels R., van Deutekom J., Janson A.A., de Bruijn J.D., Uytdehaag F., Quax P.H., Logtenberg T., Mehtali M., Bout A. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 2002, 76:4612-4620.
20. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., Kostense S., Penders G., Helmus N., Koudstaal W., Cecchini M., Wetterwald A., Sprangers M., Lemckert A., Ophorst O., Koel B., van Meerendonk M., Quax P., Panitti L., Grimbergen J., Bout A., Goudsmit J., Havenga M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 2003, 77:8263-8271.
21. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., Robbins P.D., Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia. South Africa, and the United States, Clin Diagn Lab Immunol 2004, 11:351-357.
22. DiPaolo N., Ni S., Gaggar A., Strauss R., Tuve S., Li Z.Y., Stone D., Shayakhmetov D., Kiviat N., Toure P., Sow S., Horvat B., Lieber A. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol. Ther. 2006, 13:756-765.
23. H.B. Wang, A. Kondo, A. Yoshida, S. Yoshizaki, S. Abe, L.L. Bao, N. Mizuki, M. Ichino, D. Klinman, K. Okuda, M. Shimada, Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys, Gene Ther, (2010) 17 4-13.
24. Rodriguez A., Mintardjo R., Tax D., Gillissen G., Custers J., Pau M.G., Klap J., Santra S., Balachandran H., Letvin N.L., Goudsmit J., Radosevic K. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine 2009, 27:6226-6233.
25. Soloff A.C., Liu X., Gao W., Day R.D., Gambotto A., Barratt-Boyes S.M. Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection. Eur. J. Immunol. 2009, 39:2437-2449.
26. Magalhaes I., Sizemore D.R., Ahmed R.K., Mueller S., Wehlin L., Scanga C., Weichold F., Schirru G., Pau M.G., Goudsmit J., Kuhlmann-Berenzon S., Spangberg M., Andersson J., Gaines H., Thorstensson R., Skeiky Y.A., Sadoff J., Maeurer M. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE 2008, 3:e3790.
27. Shimada M., Wang H.B., Kondo A., Xu X.P., Yoshida A., Shinoda K., Ura T., Mizuguchi H., Klinman D., Luo J.L., Bai H., Okuda K. Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy. Gene Ther. 2009, 16:218-228.
28. Tsujimura A., Shida K., Kitamura M., Nomura M., Takeda J., Tanaka H., Matsumoto M., Matsumiya K., Okuyama A., Nishimune Y., Okabe M., Seya T. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem. J. 1998, 330(Pt 1):163-168.
29. Shingai M., Inoue N., Okuno T., Okabe M., Akazawa T., Miyamoto Y., Ayata M., Honda K., Kurita-Taniguchi M., Matsumoto M., Ogura H., Taniguchi T., Seya T. Wild-type measles virus infection in human CD46/CD150-transgenic mice: CD11c-positive dendritic cells establish systemic viral infection. J. Immunol. 2005, 175:3252-3261.
30. Marie J.C., Kehren J., Trescol-Biemont M.C., Evlashev A., Valentin H., Walzer T., Tedone R., Loveland B., Nicolas J.F., Rabourdin-Combe C., Horvat B. Mechanism of measles virus-induced suppression of inflammatory immune responses. Immunity 2001, 14:69-79.
31. Johansson L., Rytkonen A., Wan H., Bergman P., Plant L., Agerberth B., Hokfelt T., Jonsson A.B. Human-like immune responses in CD46 transgenic mice. J. Immunol. 2005, 175:433-440.
32. Johansson L., Rytkonen A., Bergman P., Albiger B., Kallstrom H., Hokfelt T., Agerberth B., Cattaneo R., Jonsson A.B. CD46 in meningococcal disease. Science 2003, 301:373-375.
33. Matsui H., Sekiya Y., Nakamura M., Murayama S.Y., Yoshida H., Takahashi T., Imanishi K., Tsuchimoto K., Uchiyama T., Sunakawa K., Ubukata K. CD46 transgenic mouse model of necrotizing fasciitis caused by Streptococcus pyogenes infection. Infect. Immun. 2009, 77:4806-4814.
34. Sakurai F., Kawabata K., Koizumi N., Inoue N., Okabe M., Yamaguchi T., Hayakawa T., Mizuguchi H. Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice. Gene Ther. 2006, 13:1118-1126.
35. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
36. Sakurai F., Kawabata K., Yamaguchi T., Hayakawa T., Mizuguchi H. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities. Gene Ther. 2005, 12:1424-1433.
37. Mizuguchi H., Kay M.A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 1998, 9:2577-2583.
38. Mizuguchi H., Kay M.A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 1999, 10:2013-2017.
39. Sakurai F., Mizuguchi H., Yamaguchi T., Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol. Ther. 2003, 8:813-821.
40. Maizel J.V., White D.O., Scharff M.D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968, 36:115-125.
41. Kanegae Y., Makimura M., Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J. Med. Sci. Biol. 1994, 47:157-166.
42. Koizumi N., Kawabata K., Sakurai F., Watanabe Y., Hayakawa T., Mizuguchi H. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum. Gene Ther. 2006, 17:264-279.
43. Yamaguchi T., Kawabata K., Koizumi N., Sakurai F., Nakashima K., Sakurai H., Sasaki T., Okada N., Yamanishi K., Mizuguchi H. Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Hum. Gene Ther. 2007, 18:753-762.
44. Koizumi N., Yamaguchi T., Kawabata K., Sakurai F., Sasaki T., Watanabe Y., Hayakawa T., Mizuguchi H. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J. Immunol. 2007, 178:1767-1773.
45. Stone D., Liu Y., Li Z.Y., Tuve S., Strauss R., Lieber A. Comparison of adenoviruses from species B. C, e, and f after intravenous delivery, Mol Ther 2007, 15:2146-2153.
46. Iacobelli-Martinez M., Nemerow G.R. Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J. Virol. 2007, 81:1305-1312.
47. Nanda A., Lynch D.M., Goudsmit J., Lemckert A.A., Ewald B.A., Sumida S.M., Truitt D.M., Abbink P., Kishko M.G., Gorgone D.A., Lifton M.A., Shen L., Carville A., Mansfield K.G., Havenga M.J., Barouch D.H. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J. Virol. 2005, 79:14161-14168.
48. Thorner A.R., Lemckert A.A., Goudsmit J., Lynch D.M., Ewald B.A., Denholtz M., Havenga M.J., Barouch D.H. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol. 2006, 80:12009-12016.
49. Ophorst O.J., Radosevic K., Havenga M.J., Pau M.G., Holterman L., Berkhout B., Goudsmit J., Tsuji M. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect. Immun. 2006, 74:313-320.
50. Shott J.P., McGrath S.M., Pau M.G., Custers J.H., Ophorst O., Demoitie M.A., Dubois M.C., Komisar J., Cobb M., Kester K.E., Dubois P., Cohen J., Goudsmit J., Heppner D.G., Stewart V.A. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 2008, 26:2818-2823.
51. Cattaneo R. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J. Virol. 2004, 78:4385-4388.
52. Dorig R.E., Marcil A., Chopra A., Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993, 75:295-305.
53. Santoro F., Kennedy P.E., Locatelli G., Malnati M.S., Berger E.A., Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999, 99:817-827.
54. Sakurai F., Nakamura S., Akitomo K., Shibata H., Terao K., Kawabata K., Hayakawa T., Mizuguchi H. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol. Ther. 2008, 16:726-733.
55. Zhang Y., Chirmule N., Gao G.P., Qian R., Croyle M., Joshi B., Tazelaar J., Wilson J.M. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 2001, 3:697-707.
56. Sakurai H., Tashiro K., Kawabata K., Yamaguchi T., Sakurai F., Nakagawa S., Mizuguchi H. Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vector-induced innate immune responses. J. Immunol. 2008, 180:4931-4938.
57. De Geest B., Snoeys J., Van Linthout S., Lievens J., Collen D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum. Gene Ther. 2005, 16:1439-1451.
58. Sakurai H., Kawabata K., Sakurai F., Nakagawa S., Mizuguchi H. Innate immune response induced by gene delivery vectors. Int. J. Pharm. 2008, 354:9-15.